The study, by researchers at UNC Lineberger Comprehensive Cancer Center and UNC Adams School of Dentistry, Chapel Hill, North Carolina, and Moffitt Cancer Center, Tampa, Florida, in partnership with the International Head and Neck Cancer Epidemiology (INHANCE) consortium, appeared Sept. 19, 2023, in the Journal of the National Cancer Institute.
“The INHANCE consortium’s patient data allowed us to be as thorough as possible and identify robust associations between oral health and survival,” said lead author Jason Tasoulas MD, DMD, a current PhD candidate. “We assembled a diverse and experienced team to examine records of approximately 2,500 patients from eight countries to carry out our state-of-the-art statistical analyses.”
Head and neck cancer patients were asked to self-report aspects of their oral health and hygiene, including gum bleeding, tooth brushing frequency and mouthwash use, as well as the number of natural teeth and frequency of dental visits they had during a 10-year period prior to their cancer diagnosis.
Those who had frequent dental visits (more than five visits in a reported decade) had higher overall survival at five and 10 years (74% and 60%, respectively) compared to those with no dental visits (54% at five years and 32% at 10 years). This finding was most pronounced among people with cancers of the oropharynx, which consists of the structures in the back of the throat, including the base of the tongue, tonsils and soft palate. Having no natural remaining teeth was associated with a 15% lower five-year overall survival compared to those with more than 20 natural teeth. Survival differences of less than 5%, which were not significant, were found for patient-reported gum bleeding, tooth brushing and mouthwash use.
While survival has improved during the past decades due to treatment advances, head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide and accounts for about 4% of all cancers in the United States. In 2023, an estimated 66,920 people will be diagnosed with the disease in the U.S. The main environmental risk factor for the disease is tobacco use but alcohol consumption and testing positive for the human papillomavirus also increase a person’s risk for the disease.
“This current research effort capitalizes on previous data collection efforts by our team in North Carolina through the Carolina Head and Neck Cancer Epidemiology (CHANCE) study to investigate the role of oral health in patients with head and neck squamous cell carcinoma. The present report is based on a larger-scale study, accounting for geographic variability and capturing more oral health variables,” said Kimon Divaris, DDS, PhD, study author and James Bawden Distinguished Professor at the UNC Adams School of Dentistry and UNC Gillings School of Global Public Health.
“Inspired by Dr. Divaris’ previous work, we sought out opportunities to collaborate with a larger network of epidemiologists, surgeons, physicians, dentists and scientists from all over the world to address an important but often overlooked problem for patients with head and neck squamous cell carcinoma,” said corresponding author Antonio L. Amelio, PhD, vice chair of research in the Head and Neck Oncology Department and associate member of the Tumor Biology Department at Moffitt Cancer Center, and an adjunct associate professor at the UNC Department of Otolaryngology-Head and Neck Surgery. “Our hope is that these findings become a standard part of guidelines implemented for the prevention and management of head and neck squamous cell carcinomas in the near future.”
Carole Fakhry, MD, MPH, the Charles W. Cummings M.D. Professor of Otolaryngology at Johns Hopkins School of Medicine, who was not involved in the research, called the findings significant. “This is an important study that highlights the interplay between oral health and head and neck squamous cell carcinoma and overall survival. While we seek biomarkers to predict which patient will do well, this study points out features of a history and examination that are associated with survival. Additionally, this may lead us down the road of prevention of these cancers.”
Authors and disclosures
In addition to Tasoulas, Divaris and Amelio, the article’s other authors from UNC include Siddharth Sheth DO, MPH, Wendell G. Yarbrough MD, MMHC, and Trevor Hackman MD, UNC Lineberger and UNC School of Medicine; Douglas R. Farquhar MD, MPH, and Chris B. Agala PhD, UNC School of Medicine; and Andrew F. Olshan PhD, UNC Lineberger and UNC Gillings. A complete listing of authors is available in the paper published online.
Amelio is a global advisory board member and paid consultant for the LG Chem Life Sciences Innovation Center. Sheth receives honoraria from Naveris, Medscape; Speakers’ Bureau: Exelixis; research funding from AstraZeneca/MedImmune, Merck, Inovio Pharmaceuticals; Exelixis and Regeneron. Yarbrough is a consultant for Olympus Medical Systems. All other authors declare no potential conflicts of interest.
The study was funded by:
The INHANCE Consortium was supported by NIH grants NCI R03CA113157 and NIDCR R03DE016611.
Studies participating in the pooled analysis were supported in the following locations:
- Latin America: Fondo para la Investigacion Cientifica y Tecnologica (FONCYT) Argentina, IMIM (Barcelona), Fundação de Amparo à Pesquisa do Estado de Sao Paulo (FAPESP) (No. 01/01768-2), and European Commission (IC18-CT97-0222).
- North Carolina (1994–1997): NIH (R01CA061188), and in part by a grant from the National Institute of Environmental Health Sciences (P30ES010126).
- Central Europe: World Cancer Research Fund and the European Commission INCO-COPERNICUS Program (Contract No. IC15-CT98-0332).
- The Sao Paulo & Sao Paulo2 studies were supported by the Sao Paulo Research Foundation – FAPESP (GENCAPO 04/12054-9, 10/51168-0.
- Western Europe study: Supported by European Community (5th Framework Programme, grant QLK1-CT-2001-00182).
The HN5000 study was funded by the National Institute for Health Research (NIHR) grant RP-PG-0707-10034). Support was also provided, in part, by the NCI Center Core Support Grant 5P30CA016080-42 to the UNC Lineberger Comprehensive Cancer Center, University Cancer Research Fund, a UNC Lineberger Tier 3 Developmental Award, and NIH/NIDCR R01DE030123, and by monies from the State of Florida to Moffitt Cancer Center & Research Institute.